Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, MariTide, demonstrated up to 20 percent average weight loss in people living with ...